Safety and Adverse Events of Special Interest in 825 Adults With Atopic Dermatitis Receiving Up to 12 Months of Tralokinumab Treatment in a Real-World Setting. J of Skin 2026, 10 (2), s730. https://doi.org/10.25251/7mx6d484.